A study was undertaken to assess the resources used during the management of SCT bleeds in Germany. Modelling techniques were used to estimate the potential economic impact of recombinant factor VIIa (rFVIIa) in addition to conventional treatment for such bleeds. Retrospective information on transplant type, bleed site and severity were obtained for more than 600 patients for bleeds associated with SCT from two major centres (in Idar-Oberstein and Munich). Resource utilisation data were provided from the participating physicians and the literature. Costs were obtained through a local economist, published articles, reports and personal communications. Outcome data were collected from the participating centres. In Germany, marginal costs assuming a 21 day bleed associated with the management of a GI bleed would be approximately 32,000 €. The additional cost of rFVIIa may be compensated for by a reduction in the requirement of other blood products. The marginal costs related to IC bleeds vary between 9,000 and 14,000 €, there is unlikely to be a cost saving with rFVIIa. Sensitivity analysis was undertaken to estimate the cost per additional survivor for a reduction in mortality attributable to the use of rFVIIa in an IC bleed. Results vary from 21,000 € to over 5,000,000 € per additional survivor. Care has to be taken when interpreting these results since most mortality and hence its reduction is only related to rather than caused directly by bleeding. The results would suggest that rFVIIa may lead to cost savings in GI bleeds and could be cost-effective for other types such as IC bleeds. These preliminary conclusions are dependent on clinical and economic assumptions and need to be validated with further empirical data.
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The Austrian Stem Cell Transplantation Registry (ASCTR) -report on efficient work with PROMISE B. Lindner, H. Greinix (Innsbruck, A) Since 1991 Austrian transplant data have been collected centrally and forwarded to the EBMT. D. Niederwieser, the initiator and founder of the Austrian registry, started collecting data in an Excel file. In 1998 the Austrian Registry switched to the MRDM program and in 2000 to PROMISE. At the moment around 3500 transplants from both adults and children have been collected in the PROMISE database. Since 1995 data on all BM and PBSC transplants consecutively performed in 15 Austrian stem cell transplant centers have been processed by the ASCTR. The work of the Austrian registry has become more efficient by founding the "Austrian Working Group for Stem Cell Transplantation" in 1998. All Austrian transplant centers that report MED-A-data to the ASCTR are members of this group and, apart from other activities, cooperate in data flow, data exchange and national retrospective studies using the ASCTRdata. Since 2000 H. Greinix has been the head of this working group and has initiated several studies and two working reports on registry data (Annual Report 2000 and Annual Report 2001, in collaboration with the ÖBIG (Group within the Department of Health). The group has meetings on a regular basis where issues concerning reporting of both new transplants and followups and data analyses are discussed. All legal requirements enforced by the Austrian law protecting patients' data have been fullfilled. So far, two retrospective analyses on registry data have been published in wellknown journals. All reported data is stored in the EBMT database (PROMISE) and in a local access database that is linked to the PROMISEdownload. This allows storage of additional data e.g. patients' names or addresses that are not forwarded to the EBMT. All data are linked to the PROMISE database by the UPN code that is provided by each center. The link to the access download makes it possible to construct an individual database according to special requirements and at the same time entering MED-A data directly into PROMISE. This is a feasible working model for a small national registry or for a transplant center that does not have a well working pre-designed database. We want to thank all the Austrian centers for their excellent cooperation, the EBMT London office and R. Brand for their assistance.
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Ways to improve data management quality and efficiency M. van Reen, T. Schattenberg, M. Rinkes (Nijmegen, NL) The Department of Hematology University Medical Centre Nijmegen performs about 50 allogeneic and 30 autologous stem cell transplants every year. Transplants are carried out at our department since 1981 and the registration is performed by datamanagers since 1985. A total of about 1000 MED AB reports and additional follow-ups are registered since. Registration is very time consuming, mainly because of the fact that it is not easy to obtain the right information from multiple sources such as physicians, (research) nurses and the different documents in the (electronic) patients file. In addition the data are often transmitted more then once from one system to another. In order to obtain valid and reliable data, we have made some major steps into a process towards a structured approach to improve quality of the data and efficiency of data collection at our institute. Beside the ProMISe training sessions at the EBMT congress, the EBMT manual, the use of ProMISe 1 and attending national datamanagement meetings, quality control and efficiency of data collection need more attention and improvements can easily be made in the individual EBMT centres. At our centre the quality of data (collection) is increased by the implementation of local initiatives such as regularly datamanagement meetings, defining and implementing local standard operating procedures, organising training sessions given by physicians and laboratory staff, and data control. The efficiency will raise to a higher level soon. Key elements to improve this are the identification of the data flow and the initiation of standardised procedures resulting in easy access of data. Examples are our Hematology Registration System, datacontrol and registration on paper before entering ProMISe. Future plans are to increase the quality by implementing internal monitoring, the development of, and the access to, related (laboratory) databases.
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The web-based system for BMT Registry of Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) A. Pession, R. Rondelli, F. Locatelli, M. Zecca, M. De Rosa, E. Rinieri, A. Prete, G. Dini, C. Uderzo, G 
. Paolucci on behalf of the AIEOP-BMT Group

Introduction:
Information organized in observational databases and derived from large series of consecutive patients treated in several centers provides resource for evaluating results of HSCT. It may also offers a complementary approach for addressing randomized controlled clinical trials, retrospective analyses, besides deriving data on the efficacy in different disorders. Moreover, periodic and systematic assessments of overall results in specific disease are informative and useful for physicians, regional and/or central governmental agencies, and other individual or organizations involved in health-care. Methods: Since 1985, the AIEOP BMT Registry has collected and stored data from 23 centers performing HSCT in pediatric patients nationwide. Since September 2002 a common centralized system for data collection based on Advanced Mulcicenter Research (AMR) has been adopted. The webbased system allows the management of the whole informative flow: from data entry, to monitoring and on-line analysis. Participating teams are required to register all consecutive transplants adopting the web-based database for all AIEOP cases registration (Mod.1.01). Both the systems are created by Oracle and protected by IANUS® technology, implemented at Interuniversity Computing Center (CINECA), in Bologna, and organized at the AIEOP Operation Office, and structurally integrated with other specific, diseaseoriented national databases. Dedicated on-line procedures are available for partners which need a periodical data exchange. Results. Until December 2001, the AIEOP BMT Registry database includes information on 3678 HSCT performed in 3189 patients aged 0 -17 yrs. The monitored population represents more than 90% of procedures performed in childhood. These data have provided the basis for several retrospective analyses and prospective trials published by the Registry. Discussion. The AIEOP web-based system for HSCT patients offers a unique example of transplant registry dedicated to pediatric patients and organized according to AMR model. The implementation of an high costing web-based technology has improved the quality of data collection, optimized the work of all operators, and facilitated the experience sharing between centers.
